Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Lymphoma

A revised international prognostic score system for Waldenström’s macroglobulinemia

Abstract

A staging system was developed a decade ago for patients with Waldenström’s macroglobulinemia (WM), however, since then WM treatments have changed. A revised staging system could better capture prognosis of WM patients in the chemoimmunotherapy era. We developed a revised system based on data from 492 symptomatic patients with at least 3 years and a median of 7 years of follow up while an independent validation cohort included 229 symptomatic patients. We identified age (≤65 vs 66–75 vs ≥76 years), b2-microglobulin ≥ 4 mg/L, serum albumin <3.5 gr/dl, and LDH ≥ 250 IU/L (ULN < 225) to stratify patients in five different prognostic groups and identify a very-low risk as well as a very-high risk group with a 3-year WM-related death rate of 0, 10, 14, 38, and 48% (p < 0.001) and 10-year survival rate of 84, 59, 37, 19, and 9% (p < 0.001). We evaluated this staging system separately in patients >65 years and <65 years, according to the reason for initiation of treatment, among patients receiving frontline rituximab or in patients treated primarily without rituximab. With further validation before clinical use, this revised IPSSWM could improve WM patient risk stratification, is easily available and may be used in the everyday practice to provide prognostic information.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Fig. 1
Fig. 2
Fig. 3

References

  1. Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML, et al. Clinicopathological definition of Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol. 2003;30:110–5.

    Article  Google Scholar 

  2. Kastritis E, Kyrtsonis MC, Morel P, Gavriatopoulou M, Hatjiharissi E, Symeonidis AS, et al. Competing risk survival analysis in patients with symptomatic Waldenstrom macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy. Haematologica. 2015;100:e446–9.

    CAS  Article  Google Scholar 

  3. Dhodapkar MV, Hoering A, Gertz MA, Rivkin S, Szymonifka J, Crowley J, et al. Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003. Blood. 2009;113:793–6.

    CAS  Article  Google Scholar 

  4. Leblond V, Kastritis E, Advani R, Ansell SM, Buske C, Castillo JJ, et al. Treatment recommendations from the Eighth International Workshop on Waldenstrom’s Macroglobulinemia. Blood. 2016;128:1321–8.

    CAS  Article  Google Scholar 

  5. Morel P, Duhamel A, Gobbi P, Dimopoulos MA, Dhodapkar MV, McCoy J, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood. 2009;113:4163–70.

    CAS  Article  Google Scholar 

  6. Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258–65.

    CAS  Article  Google Scholar 

  7. Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111:558–65.

    CAS  Article  Google Scholar 

  8. Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 2015;33:2863–9.

    CAS  Article  Google Scholar 

  9. Kastritis E, Kyrtsonis MC, Hadjiharissi E, Symeonidis A, Michalis E, Repoussis P. et al. Greek Myeloma Study Group Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom’s macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH). Leuk. Res. 2010;34:1340–3.

    CAS  Article  Google Scholar 

  10. Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, et al. Ibrutinib in previously treated Waldenstrom’s macroglobulinemia. N Engl J Med. 2015;372:1430–40.

    CAS  Article  Google Scholar 

  11. Dimopoulos MA, Trotman J, Tedeschi A, Matous JV, Macdonald D, Tam C, et al. Ibrutinib for patients with rituximab-refractory Waldenstrom’s macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol. 2017;18:241–50.

    CAS  Article  Google Scholar 

  12. Kyle RA, Treon SP, Alexanian R, Barlogie B, Bjorkholm M, Dhodapkar M, et al. Prognostic markers and criteria to initiate therapy in Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol. 2003;30:116–20.

    Article  Google Scholar 

  13. Royston P, Altman DG. External validation of a Cox prognostic model: principles and methods. BMC Med. Res. Methodol. 2013;13:33.

    Article  Google Scholar 

  14. Levitt DG, Levitt MD. Human serum albumin homeostasis: a new look at the roles of synthesis, catabolism, renal and gastrointestinal excretion, and the clinical value of serum albumin measurements. Int J Gen Med. 2016;9:229–55.

    CAS  Article  Google Scholar 

  15. Bairey O, Shacham-Abulafia A, Shpilberg O, Gurion R. Serum albumin level at diagnosis of diffuse large B-cell lymphoma: an important simple prognostic factor. Hematol Oncol. 2016;34:184–92.

    CAS  Article  Google Scholar 

  16. Melchardt T, Troppan K, Weiss L, Hufnagl C, Neureiter D, Trankenschuh W, et al. A modified scoring of the NCCN-IPI is more accurate in the elderly and is improved by albumin and beta2 -microglobulin. Br J Haematol. 2015;168:239–45.

    CAS  Article  Google Scholar 

  17. Dalia S, Chavez J, Little B, Bello C, Fisher K, Lee JH, et al. Serum albumin retains independent prognostic significance in diffuse large B-cell lymphoma in the post-rituximab era. Ann Hematol. 2014;93:1305–12.

    CAS  Article  Google Scholar 

  18. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412–20.

    Article  Google Scholar 

  19. Ghobrial IM, Fonseca R, Gertz MA, Plevak MF, Larson DR, Therneau TM, et al. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. Br J Haematol. 2006;133:158–64.

    Article  Google Scholar 

  20. Buske C, Sadullah S, Kastritis E, Tedeschi A, Garcia-Sanz R, Bolkun L, et al. Treatment and outcome patterns in European patients with Waldenstrom’s macroglobulinaemia: a large, observational, retrospective chart review. Lancet Haematol. 2018;5:e299–309.

    Article  Google Scholar 

  21. Kapoor P, Ansell SM, Fonseca R, Chanan-Khan A, Kyle RA, Kumar SK, et al. Diagnosis and management of Waldenstrom Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. JAMA Oncol. 2017;3:1257–65.

    Google Scholar 

  22. Dimopoulos MA, Kastritis E, Delimpassi S, Zomas A, Kyrtsonis MC, Zervas K. The international prognostic scoring system for Waldenstrom’s macroglobulinemia is applicable in patients treated with rituximab-based regimens. Haematologica. 2008;93:1420–2.

    CAS  Article  Google Scholar 

  23. Dimopoulos MA, Tedeschi A, Trotman J, Garcia-Sanz R, Macdonald D, Leblond V, et al. Phase 3 rial of Ibrutinib plus Rituximab in Waldenstrom’s macroglobulinemia. N Engl J Med. 2018;378:2399–410.

    CAS  Article  Google Scholar 

  24. Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y, et al. MYD88 L265P somatic mutation in Waldenstrom’s macroglobulinemia. N Engl J Med. 2012;367:826–33.

    CAS  Article  Google Scholar 

  25. Treon SP, Cao Y, Xu L, Yang G, Liu X, Hunter ZR. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood. 2014;123:2791–6.

    CAS  Article  Google Scholar 

  26. Abeykoon JP, Paludo J, King RL, Ansell SM, Gertz MA, LaPlant BR, et al. MYD88 mutation status does not impact overall survival in Waldenstrom macroglobulinemia. Am J Hematol. 2018;93:187–94.

    CAS  Article  Google Scholar 

  27. Treon SP, Xu L, Hunter Z. MYD88 mutations and response to Ibrutinib in Waldenstrom’s macroglobulinemia. N Engl J Med. 2015;373:584–6.

    CAS  Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Meletios A. Dimopoulos.

Ethics declarations

Conflict of interest

EKastritis has received honoraria from Amgen, Genesis Pharma, Janssen, Takeda, Prothena; PM has consulting or advisory role to Janssen; AD has consulting or advisory role to MSD; LY has received honoraria from Abbvie, Janssen, Roche, Gilead and has consulting or advisory role to Abbvie, Roche, Janssen, Gilead, has research funding from Roche & Janssen; KL has received honoraria from Novartis, has consulting or advisory role with Takeda, Amgen, Gilead, Novartis and has received research funding from Roche, Novartis, Takeda, Sandoz, Teva, Mundipharma; EH has received honoraria from Janssen, Roche, Winmedica; MV has advisory role to Janssen and Roche; NG has received honoraria from Takeda, Amgen, Janssen, Genesis Pharma and has a consulting or advisory role to Takeda, Amgen, Janssem, Genesis Pharma; GM has participated in advisory boards of Janssen, Takeda, Ionis, MAD has received honoraria from Amgen, Celgene, Janssen, Takeda. The remaining authors declare that they have no conflict of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kastritis, E., Morel, P., Duhamel, A. et al. A revised international prognostic score system for Waldenström’s macroglobulinemia. Leukemia 33, 2654–2661 (2019). https://doi.org/10.1038/s41375-019-0431-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-019-0431-y

Further reading

Search

Quick links